ACTICOAT^◊

About ACTICOAT

Act with certainty with ACTICOAT antimicrobial barrier dressings - the right dressing at the right time.

Proven effective in acute, chronic and burn wound management, in both community and hospital settings.

ACTICOAT has a unique, patented construction with nanocrystalline technology.

	Bactericidal in as little as 30 minutes to improve healing times^1-4
	All signs and symptoms of infection eliminated in 60% of wounds within 2 weeks⁵
	Reduces the instances and minimises the progression of wound infection through prophylactic or early application⁶
	Staff and budgetary cost of dressing changes alleviated, by releasing sufficient silver to remain effective for up to 3 or 7 days*^7-12
	Up to 50% cost savings per wound when compared to alternative dressings**, promting better outcomes for your patients¹³

Control costs and alleviate staff burden, with no compromise on the quality of patient care^2-5

Sizes and ordering information

Contact us to discover how ACTICOAT can help your staff and your budget.

*ACTICOAT & ACTICOAT Flex 3 for 3-day use. ACTICOAT 7 & ACTICOAT Flex 7 for 7-day use.
**ComfeelTM , BiatainTM Ag or AcqucelTM Ag

References

1. Wright et al (1998) ‘Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment’, American Journal of Infection Control: 26(6):572-577.
2. Wright et al (1998) 'Efficacy of topical silver against fungal burn wound pathogens', American Journal of Infection Control (1999); 27(4): 344-350.
3. Driffield, K; ACTICOAT Flex 3 has antimicrobial activity in 30 minutes, Data on file 0810018, Smith & Nephew.
4. Driffield, K; ACTICOAT Flex 7 has antimicrobial activity in 30 minutes, Data on file 0810014, Smith & Nephew.
5. Gago et al (2008). A comparison of Three Silver - containing Dressings in the Treatment of Infected, Chronic Wounds 20(10): 273-278.
6. Newton (2010) Reducing MRSA bacteraemias associated with wounds. Wounds UK, Vol 6, No 1
6. Westaim Report Ref: # 971030 'The Antimicrobial Activity of Westaim's ACTICOAT Silver Coated Dressing against Clinically Relevant Organisms over an Extended Period of Time'.
8. Driffield, K; Antimicrobial Activity of ACTICOAT Flex 3 against a Broad Spectrum of Wound Pathogens, Data on File reference 0810016.
9. Newton (2010) Reducing MRSA bacteraemias associated with wounds. Wounds UK, Vol 6, No 1
10. Sibbald et al (2001) A screening evaluation of an ionised nanocrystalline silver dressing in chronic wound care. Ostomy Wound management 47 (10), 38-4.
11. Selcuk (2012) Comparison of the antibacterial effect of silver. Burns 38: 1204-1209.
12. Chopra (2007) Increasing use of silver-based products. Jnl. Anti Chem. 17. Strohal (2005). Nanocrystalline silver dressings. Jul Hospital 226-230
13. Upton, D (2010) Pain and stress as contributors to delayed wound healing. Wound Practice and Research.
14. Driffield, K; Antimicrobial activity of ACTICOAT Flex 7 against a broad spectrum of wound pathogens, Data on file 0810012, Smith & Nephew.
15. Driffield, K; Antimicrobial activity of ACTICOAT Flex 7 dressings in a seven-day repeat challenge, Data on file 0810013, Smith & Nephew.
16. Driffield, K; Antimicrobial Activity of ACTICOAT Flex 3 against a Broad Spectrum of Wound Pathogens, Data on File reference 0810016.
17. Driffield, K; Antimicrobial activity of ACTICOAT Flex 3 in a three-day repeat challenge, Data on file 0810017, Smith & Nephew.
18. Westaim (Sherritt) Report Ref: 93/001 'Broad Spectrum Efficacy'.
19. Westaim Report Ref. #010322 ‘Seven Day Efficacy of ACTICOAT 7 Dressings Against Multiple Organisms’.
20. Daubney, L: Silver Release Testing of ACTICOAT Flex 7 Dressings. Report reference DS/08/062/R2.
21. Daubney, L: Silver Release Testing of ACTICOAT Flex 3 Dressings. Report reference DS/08/078/R2.
22. Cuttle L et al., (2007) A retrospecc cohort. Burns; 33 (6): 701-7 7.
23. Huang (2007) A randomised comparative. Burns. 33: 161-166.
24. Demling and Desanti (2002) The rate of re-epithialization.
25. Data on File Report Reference 1609015 dated August 2016. ACTICOAT™ and ACTICOAT Flex 3 when used in conjunction with ALLEVYN™ Gentle Border using log reduction methodology against P.aeruginosa and MRSA.
26. Peters and Vercher (2006) Healing at. Jnl Burn Care & Res Vol27. No 2.
27. Tonkin and Wood (2006) Nanocrystalline Silver. Vol 13. No 4.
28. Muangman (2006) Comparison of efficacy. J Med Assoc Vol89 No7.
29. Fong (2005) A silver coated dressing. Burns 31: 562-567.
30. Leo Nherera. Cost-effectiveness analysis of antimicrobials in the management of superficial and deep partial thickness burns. Health Economics Manager, Smith & Nephew.
31. Strand (2010) Ann-Burns-and-Fire-Disasters-23-182.
32. Nheera (2015) Quantifying the cost savings. SAWC Poster.
33. Silver (2007) A silver coated. Am Burn Assoc. 715.
34. Cheng (2004) A tale of two dressings. Queensland.
35. Data on File Report 0305001 In-Vitro Assessment of The Compatibility of ACTICOAT* And INTRASITE* Gel Dressings May 2003.
36. Data on file report 0403006 Bio-activity of ACTICOAT™ when used with INTRASITE™ Gel March 2014.
37. File Report Reference 1609015 dated August 2016. ACTICOAT™ and ACTICOAT Flex 3 when used in conjunction with ALLEVYN™ Gentle Border using log reduction methodology against P.aeruginosa and MRSA.
38. Data on File Report Reference 1610016 dated October 2016. ACTICOAT™ and ACTICOAT Flex 3 when used in conjunction with ALLEVYN™ Classic range of dressings: A review of clinical data.
39. Data on File Report Reference 1610017 dated October 2016. ACTICOAT™ and ACTICOAT Flex 3 when used in conjunction with ALLEVYN™ LIFE: A review of clinical data.
40. West P and Gunning P (2006) Visualisation of silver levels in 2 silver dressings using scanning electron microscopy and energy dispersive X-ray microanalysis. Poster at SAWC meeting San Antonio.
41. Woodmansey (2006) A visual demonstration of the antimicrobial efficacy of silver-based dressings against key pathogenic bacteria using confocal laser scanning microscopy.
42. Roberts (2008) Use of interventional approaches to controlling healthcare-acquired infections in wounds. The role of silver, Journal of Wound Technology, No.2: 58-60.

Acute or chronic setting

The right dressing for positive patient outcomes.

Proactive wound management

ACTICOAT has proven clinically effective in preventing the spread of localised and systemic infections in critically colonised wounds, reducing nursing time and improving patient quality of life^2-5

ACTICOAT can potentially save nursing time and cut the cost per wound by up to 50% when compared to alternative dressings**^1-2

ACTICOAT should be used immediately when an infection is identified

	Fights bacteria within 30 minutes of application*^1-4
	Provides broad spectrum efficacy against over 150 pathogens, including positive and negative gram bacteria, yeasts and fungal infections, and MRSA when used as a protective barrier^1-2,14-18
	3 or 7 days of uninterrupted use with sustained release of silver, requiring fewer dressing changes^{7,14-17,19-21}
	Low-adherent, high wet tensile strength for one-piece removal and reduced wound bed trauma⁴

In clinical testing, patients treated with ACTICOAT over 8 weeks were twice as likely to heal completely when compared to alternative silver dressings**⁵

For more challenging wounds, our PICO^◊ and RENESYS^◊ products can provide Negative Pressure Wound Therapy (NPWT), and be used in conjunction with ACTICOAT for up to 3 days.

*during in-vitro study
**ComfeelTM, BiatainTM Ag or AquacelTM Ag

References

Effective against burns

ACTICOAT has proven highly effective against burn wound infections.

Early application can heal wounds faster^22-24, improving your patient’s comfort and quality of life.


	Infection rate reduced by 80%²⁵
	A 90% reduction in the use of antibiotics²⁵
	A significant reduction in the need for skin grafts or other surgical procedures^{22, 26-28}

Proactive burn wound treatment.

Prophylactic use can provide an antimicrobial barrier, following removal of necrotic or heavily infected tissue, for:
- Deep partial thickness burns: slows wound colonisation before definitive surgery²⁹
- Superficial partial thickness burns: prevents wound progression and aids epithelialisation²²

ACTICOAT can save costs and alleviate staff workloads.

	40% reduced cost for burn wound dressings, when compared to alternative dressings*³⁰
	Length of hospital stay reduced by up to 4.75 days²⁹

Overall average total cost per patient treatment is up to 27% lower with ACTICOAT, when compared to other dressings^{26, 28, 31-34}

ACTICOAT can be used in conjunction with:
- VERSAJET^◊ for improved debridement.
- INTRASITE^◊ where additional moisture is required^35-36
- ALLEVYN^◊as an effective secondary dressing^37-39

For more challenging burn wounds, our PICO^◊and RENASYS^◊ products can provide Negative Pressure Wound Therapy (NPWT) for up to 3 days when used in conjunction with ACTICOAT.

Get Closer To Zero infections in wound management

Contact u s for advice on product selection for any specific patient requirements.

*£4,000 less than MepilexTM Ag, and £2,500 less than AquacelTM Ag

References

Innovative construction

Innovative, patented microbial dressing construction

The power of nanocrystalline silver

ACTICOAT has a unique structure, providing a large surface area for effective antimicrobial performance..

- Enables more silver to make contact with wound fluid⁴⁰- Delivers sufficient silver, with consistent concentration, to remain bactericidal⁴¹

Low-dosage silver dressings can risk becoming inactive. ACTICOAT offers the confidence and reliability you need for the right patient outcomes⁴²

Patented dressing construction

ACTICOAT: 2-layered, low-adherent silver dressing. Use for up to 3 days^7,16,21
ACTICOAT 7: 5-layered, ultra-absorbent silver dressing. Use for up to 7 days^{14-15, 19-20}
ACTICOAT Flex 3 & ACTICOAT Flex 7: Fully conformable to body contours to minimise wound bed trauma during dressing changes, effective for 3 or 7 days^{7,14-17,20-21}

Sizes and ordering information

The unique construction of ACTICOAT promotes and retains a moist environment at the wound surface.

Contact us for advice and guidance on product selection, application or removal.

References

Challenging & complex needs

Understanding your needs and the importance of patient care.

For the varying needs of your patient, such as more challenging wounds, we offer a range of additional and complimentary products where your expertise determines a more complex approach.

For more challenging wounds, our PICO^◊ and RENESYS^◊ products can provide highly effective Negative Pressure Wound Therapy (NPWT), and can be used in conjunction with ACTICOAT for up to 3 days.

	VERSAJET^◊ for improved debridement.
	INTRASITE^◊ where additional moisture is required¹
	ALLEVYN^◊as an effective secondary dressing²

Look to heal with MolecuLight i:X^TM
Patented, innovative fluorescent imaging technology to highlight bacteria and provide targeted debridement and wound management. Contact us to find out more.

Contact us now to discuss any complex or challenging cases you may have.

References

ACTICOAT^◊

About ACTICOAT

Act with certainty with ACTICOAT antimicrobial barrier dressings - the right dressing at the right time.

Proven effective in acute, chronic and burn wound management, in both community and hospital settings.

Sizes and ordering information

*ACTICOAT & ACTICOAT Flex 3 for 3-day use. ACTICOAT 7 & ACTICOAT Flex 7 for 7-day use.
**ComfeelTM , BiatainTM Ag or AcqucelTM Ag

Acute or chronic setting